Breast Cancer Following Radiotherapy and Chemotherapy among Young Women with Hodgkin Disease

JAMA

Volumn 290, Issue 4, 2003, Pages 465-475

  Travis, Lois B ^a   Hill, Deirdre A ^a   Dores, Graça M ^a   Gospodarowicz, Mary ^b   Van Leeuwen, Flora E ^c   Holowaty, Eric ^d   Glimelius, Bengt ^e   Andersson, Michael ^f   Wiklund, Tom ^g   Lynch, Charles F ^h   Van'T Veer, Mars B ⁱ   Glimelius, Ingrid ^e   Storm, Hans ^f   Pukkala, Eero ^j   Stovall, Marilyn ^k   Curtis, Rochelle ^a   Boice, John D ^l,m   Gilbert, Ethel ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d CANCER CARE ONTARIO   (Canada)

^e UPPSALA UNIVERSITY   (Sweden)

^f DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h UNIVERSITY OF IOWA   (United States)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j FINNISH CANCER REGISTRY   (Finland)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^m VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ANAMNESIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CASE CONTROL STUDY; CAUSE OF DEATH; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HODGKIN DISEASE; HORMONAL REGULATION; HUMAN; MAJOR CLINICAL STUDY; OVARY; POPULATION RESEARCH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIATION HAZARD; RISK ASSESSMENT; RISK FACTOR; SECOND CANCER; UNITED STATES; BREAST; BREAST TUMOR; MULTIMODALITY CANCER THERAPY; RADIATION EXPOSURE; RADIATION INJURY; RISK;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; FEMALE; HODGKIN DISEASE; HUMANS; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; OVARY; RADIOTHERAPY DOSAGE; RISK;

EID: 0037778770     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.4.465     Document Type: Article

References (62)

1. Peters MV. Study of survivals in Hodgkin's disease treated radiologically. Am J Roentgenol Rad Therapy. 1950;63:299-311.
2. National Cancer Institute. SEER Cancer Statistics Review, 1973-1999. Bethesda, Md: National Cancer Institute; 2002. Available at: http://seer.cancer.gov/csr/1973-1999. Accessibility verified June 30, 2003.
3. Arseneau JC, Sponzo RW, Levin DL, et al. Non-lymphomatous malignant tumors complicating Hodgkin's disease: possible association with intensive therapy. N Engl J Med. 1972;287:1119-1122.
4. Boice JD Jr. Second cancer after Hodgkin's disease: the price of success? J Natl Cancer Inst. 1993;85:4-5.
5. Mauch PM, Kalish LA, Marcus KC, et al. Long-term survival in Hodgkin's disease. Cancer J Sci Am. 1995;1:33.
6. Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol. 1997;8:115-118.
7. Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's disease. Ann Oncol. 1992;3:117-128.
8. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among lorg-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484-3494.
9. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 1993;85:25-31.
10. Travis LB, Curtis RE, Boice JD Jr. Late effects of treatment for childhood Hodgkin's disease. N Engl J Med. 2003;95:971-980.
11. Aisenberg AC. Problems in Hodgkin's disease management. Blood. 1999;93:761-779.
12. van Leeuwen FE, Klokman WJ, Van't Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18:487-497.
13. Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice JD Jr. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res. 2002;158:220-235.
14. Ng AK, Mauch PM. Radiation therapy in Hodgkin's lymphoma. Semin Hematol. 1999;36:290-302.
15. Connors JM, Noordijk EM, Horning SJ. Hodgkin's lymphoma: basing the treatment on the evidence. Hematology (Am Soc Hematol Educ Program). 2001:178-193.
16. Canellos GP. Primary treatment of Hodgkin's disease. Ann Oncol. 2002;13:153-158.
17. Wolden L, Hancock SL, Carlson RW, Goffinet DR, Jeffrey SS, Hoppe RT. Management of breast cancer after Hodgkin's disease. J Clin Oncol. 2000;18:765-772.
18. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000;18:498-509.
19. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer Incidence in Five Continents. Vol 7, No. 143. Lyon, France: IARC; 1997.
20. van Leeuwen FE, Klokman WJ, Stovall M, et al. The roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst. In press.
21. Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med. 1999;340:351-357.
22. Diller L, Narcarrow CM, Shaffer K, Matulonis U, Mauch P, Neuberg D. Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. J Clin Oncol. 2002;20:2085-2091.
23. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002;94:182-192.
24. Central axis depth dose data for use in radiotherapy: a survey of depth doses and related data measured in water or equivalent media. Br J Radiol Suppl. 1983;17:1-147.
25. Philips Medical Systems. Radiation Oncology Systems: Pinnacle3. Available at: http://www.medical.philips.com/main/products/ros/products/pinnacle3/. Accessibility verified June 5, 2003.
26. Stovall M, Smith SA, Rosenstein M. Tissue doses from radiotherapy of cancer of the uterine cervix. Med Phys. 1989;16:726-733.
27. Stovall M, Blackwell R, Cundiff J, et al. Fetal dose from radiotherapy with photon beams: report of AAPM Radiation Therapy Committee Task Group No. 36 [published correction appears in Med Phys. 1995;22:1353-1354]. Med Phys. 1995;22:63-82.
28. Stovall M, Blackwell R, Cundiff J, et al. Fetal dose from radiotherapy with photon beams: report of AAPM Radiation Therapy Committee Task Group No. 36 [published correction appears in Med Phys. 1995;22:1353-1354]. Med Phys. 1995;22:63-82.
29. Breslow NE, Day NE. Statistical methods in cancer research, volume I: the analysis of case-control studies. IARC Sci Publ. 1980;32:5-338.
30. Preston DL, Lubin JH, Pierce DA. EPICURE User's Guide. Seattle, Wash: HiroSoft International Corporation; 1991.
31. United National Scientific Committee on the Effects of Atomic Radiation (UNSCEAR). UNSCEAR 2000 Report to General Assembly, With Scientific Annexes, Sources and Effects of Ionizing Radiation. New York, NY: United Nations; 2000.
32. DeVita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970;73:881-895.
33. Shore RE, Woodard ED, Hempelmann LH, Pasternack BS. Synergism between radiation and other risk factors for breast cancer. Prev Med. 1980;9:815-822.
34. Zellmer DL, Wilson JF, Janjan NA. Dosimetry of the breast for determining carcinogenic risk in mantle irradiation. Int J Radiat Oncol Biol Phys. 1991;21:1343-1351.
35. Christie DR, Wills R, Drew JF, Barton MB. The doses received by the breast during mantle radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:223-226.
36. Prosnitz LR. Reducing treatment-related morbidity and mortality in early-stage Hodgkin's disease and why the recent Southwest Oncology Group trial is not the way to go. J Clin Oncol. 2002;20:2225-2228.
37. Boice JD Jr. Radiation and breast carcinogenesis. Med Pediatr Oncol. 2001;36:508-513.
38. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996;334:745-751.
39. Yahalom J, Petrek JA, Biddinger PW, et al. Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol. 1992;10:1674-1681.
40. Peters MH, Sonpal IM, Batra MK. Breast cancer in women following mantle irradiation for Hodgkin's disease. Am Surg. 1995;61:763-766.
41. Aisenberg AC, Finkelstein DM, Doppke KP, Koerner FC, Boivin JF, Willett CG. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer. 1997;79:1203-1210.
42. Lucraft HH. Strategies to reduce deaths from breast cancer following mantle irradiation. Clin Oncol (R Coll Radiol). 2000;12:276-277.
43. Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev. 2000;26:291-302.
44. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst. 1972;48:605-613.
45. Schairer C, Person I, Falkeborn M, Naessen T, Troisi R, Brinton LA. Breast cancer risk associated with gynecologic surgery and indications for such surgery. Int J Cancer. 1997;70:150-154.
46. Titus-Ernstoff L, Longnecker MP, Newcomb PA, et al. Menstrual factors in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998;7:783-789.
47. Ray GR, Trueblood W, Enright LP, Kaplan HS, Nelsen TS. Oophoropexy: a means of preserving ovarian function following pelvic megavoltage radiotherapy for Hodgkin's disease. Radiology. 1970;96:175-180.
48. Williams RS, Littell RD, Mendenhall NP. Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease. Cancer. 1999;86:2138-2142.
49. Darby SC, Reeves G, Key T, Doll R, Stovall M. Mortality in a cohort of women given x-ray therapy for metropathia haemorrhagica. Int J Cancer. 1994;56:793-801.
50. Boice JD Jr, Blettner M, Kleinerman RA, et al. Radiation dose and breast cancer risk in patients treated for cancer of the cervix. Int J Cancer. 1989;44:7-16
51. Horning SJ, Hoppe RT, Kaplan HS, Rosenberg SA. Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med. 1981;304:1377-1382.
52. Bokemeyer C, Schmoll HJ, van Rhee J, Kuczyk M, Schuppert F, Poliwada H. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkins lymphoma. Ann Hematol. 1994;68:105-110.
53. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 2001;7:535-543.
54. Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol. 1982;144:511-518.
55. Persson L, Adami H-O, Lindberg BS, Johansson EDB, Manell P. Practice and patterns of estrogen treatment in climacteric women in a Swedish population: a descriptive epidemiological study, part I. Acta Obstet Gynecol Scand. 1983;62:289-296.
56. Jolleys JV, Olesen F. A comparative study of prescribing of hormone replacement therapy in USA and Europe. Maturitas. 1996;23:47-53.
57. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000;283:485-491.
58. Chen C-L, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287:734-741.
59. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood Cancer Survivor Study. J Natl Cancer Inst. 2001;93:618-629.
60. Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM, eds. Hodgkin's Disease. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999.
61. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, of MOPP alternating with ABVD. N Engl J Med. 1992;327:1478-1484.
62. Brusamolino E, Lunghi F, Orlandi E, et al. Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity. Haematologica. 2000;85:1032-1039.